Skeletal Muscle Metastasis from lung cancer is a rare phenomenon. In this case report FDG PET/CT imaging detected unexpected metastatic spread in skeletal muscles from lung cancer.
Research Article
Uncommon Disseminated Muscular Metastasis from Lung Adenocarcinoma in a 18F-FDG PET/CT Study
https://doi.org/10.21203/rs.3.rs-1701212/v1
This work is licensed under a CC BY 4.0 License
You are reading this latest preprint version
Skeletal Muscle Metastasis from lung cancer is a rare phenomenon. In this case report FDG PET/CT imaging detected unexpected metastatic spread in skeletal muscles from lung cancer.
Lung cancer
PET/CT
muscle metastasis
detection
18F-FDG PET/CT is an useful imaging for the detection of primary lung cancer site and of his metastatic lesions. In this case report it’s evidenced a multiple metastatic spread in skeletal muscles.
A 51-year-old man with multiple subcutaneous nodular lesions of suspected oncologic origin referred to our Nuclear Medicine Department in order to find out the culprit primary lesion.
The 18F-FDG PET/CT study demonstrated an increased FDG uptake in the primary tumor located in the upper lobe of the left lung and multiple hypermetabolic nodular lesions in various skeletal muscle (Figs. 1, 2 and 3), also of the tongue muscles (Fig. 4).
Surgical biopsy from hypermetabolic muscle mass in the postero-inferior thoracic wall revealed to be a metastatic site from adenocarcinoma of lung origin staining with cytokeratin-7, but thyroid transcription factor-1 and cytokeratin-20 were negative. Also thyroid transcription factor-1 was negative and this factor may occur in 28% of cases with lung adenocarcinoma (1).
FDG PET/CT scan in this case demonstrated to be an excellent imaging method in detecting muscle involvements in lung cancer patients, that are a rare site of metastatic involvement from adenocarcinoma lung cancer (2,3).
DISCLOSURE STATEMENT AND ACKNOLEDGMENTS
Ethical approval and consent to participate: this article does not contain any studies with animals performed by any of the authors. All procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Consent for publication: consent was obtained from the patient for the anonymous publication of clinical and imaging data for scientific purposes.
Availability of data and material: not applicable
Competing interests: not applicable
Funding: not applicable
Author contribution: only Sara Pacella contributed to this paper
Acknowledgements: not applicable.
Conflict of interest: The author declares that she has no conflicts of interest.
Editorial decision: Major revision
07 Jul, 2022
Reviewer #2 agreed at journal
05 Jun, 2022
Reviewers agreed at journal
02 Jun, 2022
Reviewers invited by journal
02 Jun, 2022
Reviewer #1 agreed at journal
01 Jun, 2022
Editor assigned by journal
01 Jun, 2022
Submission checks completed at journal
31 May, 2022
Editor invited by journal
31 May, 2022
First submitted to journal
27 May, 2022
You are reading this latest preprint version